GEN Exclusives

More »

GEN News Highlights

More »
Mar 7, 2011

AstraZeneca Teams Up with Galderma to Develop Dermatological Therapies

  • AstraZeneca and Galderma Pharma are joining forces to develop treatments for dermatological conditions. Galderma will evaluate compounds from AstraZeneca’s existing pipeline for their potential to treat a range of skin diseases like acne, atopic dermatitis, and psoriasis.

    According to the deal Galderma will have exclusive access to a number of AstraZeneca’s compounds. Initial targets have already been identified from disease areas as diverse as oncology, inflammation, and central nervous system disorders.

    “This partnership is an example of how we are leveraging our science in new and creative ways through collaborations with recognized experts outside of AstraZeneca’s core therapy areas,” notes Clive Morris, head of the new opportunities innovative medicines unit at AstraZeneca. “Partnering with Galderma, a world leader in dermatology, is the most efficient and effective way to unlock the potential of our compounds in this rapidly evolving disease area.”

    Galderma was founded in 1981 and has 31 affiliates around the world. The firm says that it invests approximately 20% of its sales each year to discover and develop new products and access innovative technologies. The company’s laboratory in Sophia-Antipolis is focused exclusively on dermatology.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Easing Restrictions for Terminal Patients

Should the Federal Government Pass a “Right to Try” Bill Allowing Terminally Ill Patients Access to Experimental Medicines?

More »